EVMN Arthur S. Kirsch bought Evommune, Inc. shares — SEC Form 4BUYEvommune, Inc.

The stock is currently trading at $13.32, down 53.1% over the last 90 days and 33.9% over the last 30 days. It remains 59.88% below its 52-week high of $33.20.

• •Management halted further development of EVO756 for chronic spontaneous urticaria following a Phase IIb study miss on June 30, 2026.
• •The company terminated the oral drug's development in CSU on June 29, 2026, though trials in atopic dermatitis and migraine will continue.
• •Director Arthur S. Kirsch executed the largest insider purchase in the company's history on July 7, 2026.

• •The stock faces significant downside pressure due to a 17.61% short interest float and the recent failure of the Phase IIb Urticaria study to meet its primary endpoint.
• •Investors face the risk that the termination of the oral drug's development in CSU on June 29, 2026, limits near-term revenue potential.